Which of the following laboratory results would alert the nurse that a client who has diabetes is experiencing diabetic nephropathy?

A. Liver disease is relevant for certain anesthetics, so this option is not correct.

B. Ester-linked local anesthetics (such as procaine, tetracaine, and chloroprocaine) are primarily metabolized by plasma pseudocholinesterases, not by the liver. Therefore, liver disease does not significantly impact their metabolism, and they are generally safer in patients with hepatic impairment.

C. Inhaled anesthetics are primarily metabolized in the lungs, with minimal hepatic metabolism for most agents. While some volatile agents undergo partial hepatic metabolism, they are not considered significantly contraindicated in liver disease.

D. Amide-linked local anesthetics (such as lidocaine, bupivacaine, and prilocaine) are metabolized primarily in the liverby hepatic enzymes. In patients with liver disease, the metabolism of amide anesthetics can be impaired, leading to drug accumulation and increased risk of systemic toxicity. Therefore, liver disease is considered a relative contraindication, and dose adjustments or alternative agents may be needed.

A. Vasoconstrictors (such as epinephrine) cause local vasoconstriction, which reduces blood flow at the injection site. This slows the rate at which the anesthetic is absorbed into the systemic circulation. As a result, plasma drug levels remain lower, decreasing the likelihood of systemic toxicity (e.g., CNS effects like seizures or cardiovascular effects such as arrhythmias). This is particularly important with potent local anesthetics like lidocaine or bupivacaine, where high systemic levels can be dangerous.

B. Vasoconstrictors do not prevent bradycardia. Instead, they stimulate adrenergic receptors, which can lead to increased heart rate (tachycardia) and elevated blood pressureif absorbed systemically. Therefore, they are used cautiously in clients with cardiovascular disease. Preventing bradycardia is not a therapeutic goal of adding vasoconstrictors.

C. By decreasing local blood flow, vasoconstrictors delay the removal of the anesthetic from the injection site, allowing it to remain in contact with nerve fibers longer. This prolongs the duration of anesthesia, which is beneficial during longer procedures and reduces the need for repeated dosing.

D. Vasoconstrictors actually decrease (not enhance) absorptioninto systemic circulation. This is the key mechanism behind both reduced toxicity and prolonged action. Enhanced absorption would increase systemic drug levels, which is the opposite of the intended effect.

E. Because vasoconstrictors slow drug absorption and keep the anesthetic localized, they prolong rather than shortenthe duration of action. Shortening duration would require faster systemic uptake, which vasoconstrictors specifically prevent.